Marriage Counselors in Riverview, FL Accepting Medicare

7 Marriage Counselors found. Showing 1 - 7

Ronda Porter, PH. D., LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 6338 Us Highway 301 S, Riverview, FL 33578 Phone: 813-245-2148

Keri Sills-payne, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 13877 Carlow Park Dr, Riverview, FL 33579 Phone: 510-214-2486

Riley Arnemann Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 12920 Summerfield Crossing Blvd, Riverview, FL 33579 Phone: 813-998-8600

Myisha L Wallace Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 13190 Royal Pines Ave, Riverview, FL 33579 Phone: 813-520-0156

Stephanie Connel Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 10823 Boyette Rd, Riverview, FL 33569 Phone: 813-391-3495

Courtney Simon Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 6613 Thackston Dr, Riverview, FL 33578 Phone: 941-713-7401

Kaila Mccarthy, M.S. LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 6013 Brandon Cir, Riverview, FL 33578 Phone: 813-413-7575

News Archive

Slitrk5 gene linked to development of OCD-like behaviors

Researchers at the Ansary Stem Cell Institute and the Department of Psychiatry at Weill Cornell Medical College discovered that mice missing a single gene developed repetitive obsessive-compulsive-like behaviors. The genetically altered mice, which behaved much like people with a certain type of obsessive-compulsive disorder (OCD), could help scientists design new therapies for this debilitating condition.

Study identifies higher mortality risk for women with back pain

New research from Boston Medical Center identifies elevated mortality risk for women with back pain when compared to women without back pain. Back pain was not associated with mortality among men indicating long-term consequences of back pain may differ by sex.

Lyra Therapeutics announces presentation of Phase 1 clinical data for LYR-210 in CRS patients

Lyra Therapeutics, Inc., a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat diseases, today announced the presentation of Phase 1 clinical data for the company's lead therapeutic, LYR-210, for chronic rhinosinusitis, a debilitating disease caused by inflammation of the paranasal sinus tissues that affects approximately 27 million people, or 11% of the adult population in the U.S.

A review of antigen-detecting rapid diagnostic tests for COVID-19

Scientists conducted a systematic review of the use cases and performance of Ag-RDTs for detecting SARS-CoV-2.

Read more Medical News

› Verified 5 days ago